Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HSD11B1 | P28845 | 14/20 | 0.50 |
| ▸ | MDM2 | Q00987 | 2/20 | 0.42 |
| ▸ | MDM4 | O15151 | 1/20 | 0.42 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.41 |
| ▸ | TSHR | P16473 | 1/20 | 0.41 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.40 |
| ▸ | TP53 | P04637 | 1/20 | 0.39 |
| ▸ | POLB | P06746 | 1/20 | 0.38 |
| ▸ | NPBWR1 | P48145 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3830055 | 1.00 | HSD11B1 (0.50) | HSD11B1MDM2MDM4ALDH1A1TSHR | |
| SCHEMBL3832015 | 0.84 | HSD11B1 (0.67) | HSD11B1MDM2MDM4ALDH1A1TSHR | |
| SCHEMBL3832017 | 0.84 | HSD11B1 (0.67) | HSD11B1MDM2MDM4ALDH1A1TSHR | |
| SCHEMBL13567977 | 0.83 | HSD11B1 (0.50) | HSD11B1MDM2MDM4ALDH1A1TSHR | |
| SCHEMBL3828319 | 0.79 | HSD11B1 (0.49) | HSD11B1MDM2MDM4ALDH1A1TSHR | |
| SCHEMBL3828314 | 0.79 | HSD11B1 (0.49) | HSD11B1MDM2MDM4ALDH1A1TSHR | |
| SCHEMBL3827580 | 0.78 | HSD11B1 (0.55) | HSD11B1MDM2MDM4ALDH1A1TSHR | |
| SCHEMBL3827576 | 0.78 | HSD11B1 (0.55) | HSD11B1MDM2MDM4ALDH1A1TSHR | |
| SCHEMBL3834249 | 0.78 | HSD11B1 (0.53) | HSD11B1MDM2MDM4ALDH1A1TSHR | |
| SCHEMBL3834250 | 0.78 | HSD11B1 (0.53) | HSD11B1MDM2MDM4ALDH1A1TSHR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090312310-A1 | Imidazothiazole derivatives | DAIICHI SANKYO COMPANY, LIMITED (JP) | 2009-12-17 | — | — | US | disclosed |
| US-20090312310-A1 | Imidazothiazole derivatives | DAIICHI SANKYO COMPANY, LIMITED (JP) | 2009-12-17 | — | — | US | disclosed |
| US-20090312310-A1 | Imidazothiazole derivatives | DAIICHI SANKYO COMPANY, LIMITED (JP) | 2009-12-17 | — | — | US | disclosed |
| EP-2103619-A1 | IMIDAZOTHIAZOLE DERIVATIVES | Daiichi Sankyo Company, Limited (JP) | 2009-09-23 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090312310-A1 | Imidazothiazole derivatives | TP53, MDM2, TP53BP1 | HSD11B1 3978/4885MDM2 2/4885MDM4 5/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.